TMCnet News
Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinomaPARIS, May 10, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the specific route of administration for Livatag®, which is currently in a phase III clinical trial (ReLive) for the second-line treatment of hepatocellular carcinoma (primary liver cancer). Livatag® (doxorubicin Transdrug™) is based on an innovative technology allowing the formulation of doxorubicin (a chemotherapeutic agent) within nanoparticles composed of polyalkylcyanoacrylate, cyclodextrin, and poloxamer. This nanoparticle formulation provides new and promising properties, including overcoming the mechanisms of chemoresistance developed by tumor cells that affect the efficacy of chemotherapy agents. “The United States represents a significant target market for Livatag®. This new U.S. patent significantly strengthens our Livatag® intellectual property portfolio, and enhances the value of this late-stage product candidate. We look forward to the availability of data from our ReLive trial in mid-2017,” said Judith Greciet, CEO of Onxeo. The new patent provides protection of the associated claims in the U.S. until 2032, and is in addition to the previously issued patents for the same patent family in other major territories, such as Europe and Japan. An additional patent family has also been filed based on a specific composition of Livatag® nanoparticles that, f granted, would extend the patent protection of Livatag® to 2036. About Onxeo Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Onxeo’s objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications. The Company is headquartered in Paris, France with offices in Copenhagen and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596). Learn more by visiting www.onxeo.com Disclaimer
Onxeo Valerie Leroy, Investor Relations [email protected] +33 1 45 58 76 00 Media Relations Caroline Carmagnol / Simon Derbanne Alize RP [email protected] +33 6 64 18 99 59 / +33 6 38 16 26 41 Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh NewCap [email protected] +33 1 44 71 94 92 Investor Relations US Brian Ritchie LifeSci Advisors [email protected] +1 212 915 2578 |